A virtual pharmaceutical company developing systems pharmacology therapies with a focus on neurological and pulmonary disease indications.
ReNeuroGen is pursuing first-in-class systems chemico-pharmacology agents that impact multi-target disease states and set in motion a cascade of effects that hasten amelioration of symptoms.
TRIPEPTIDE MYELOPEROXIDASE INHIBITORS
KYC, our lead candidate, is a powerful agent that inhibits inflammation and processes associated with certain diseases that damage healthy cells. KYC binds myeloperoxidase (MPO), converts KYC to a free radical that inhibits the inflammatory cascade as well as MPO's production of toxic oxidants.
ReNeuroGen is currently developing KYC (N-acetyl-lysyltyrosylcysteine amide) as a treatment for Sickle Cell Disease, Multiple Sclerosis, Brain Injury (e.g., TBI -> CTE), and Bronchopulmonary Dysplasia.
Stephen Naylor, Ph.D. -- Co-Founder, CEO and Board Chairman. He was Founder, CEO and Chairman of Predictive Physiology & Medicine (PPM) Inc, one of the world’s first personalized medicine companies. He serves as an Advisory Board Member of CureHunter Inc, a computational biology drug discovery company, and as a business adviser to the not-for-profit Cures Within Reach. In the past, he has held professorial chairs in Biochemistry & Molecular Biology, Pharmacology, Clinical Pharmacology, and Biomedical Engineering at Mayo Clinic in Rochester, Minnesota. He holds a Ph.D. from the University of Cambridge (UK) and undertook an NIH-funded fellowship at MIT located in the ‘other’ Cambridge. He has raised over $100M for research and corporate efforts.
Kirkwood A. Pritchard, Jr., Ph.D. -- Co-Founder, CSO and Board Director. He is a tenured Research Professor in the Division of Pediatric Surgery, Department of Surgery, at the Medical College of Wisconsin (Milwaukee, Wisconsin). He has broad and diverse translational research interests in a number of disease indications including, stroke, multiple sclerosis, traumatic brain injury, sickle cell disease, and bronchopulmonary dysplasia in premature babies. He holds a Ph.D. from Ohio State University and undertook a postdoctoral fellowship at Albert Einstein College of Medicine. He has raised over $15M for research efforts.
Billy W. Day, Ph.D. -- COO. He has basic and applied research interests in medicinal, analytical, computational, and toxicological chemistry, and in biomarker discovery/quantitation. In the past, he was professor of Pharmaceutical Sciences, of Chemistry, and of Computational & Systems Biology at the University of Pittsburgh. He was also Chief Science Consultant at the disease modeling company Immunetrics, Inc. He received a Ph.D. in Medicinal Chemistry from the University of Oklahoma Health Sciences Center and was a postdoctoral fellow in Toxicology and Chemistry at MIT. He has raised over $25M for research and corporate efforts.